{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:08:24Z","timestamp":1792602504432,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jhep.2020.11.026","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T20:04:10Z","timestamp":1606334650000},"page":"931-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Systemic treatment of HCC in special populations"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-272X","authenticated-orcid":false,"given":"Nicola","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Czauderna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-8891","authenticated-orcid":false,"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0621","authenticated-orcid":false,"given":"Peter","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.11.026_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.026_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.026_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.026_bib7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2020.11.026_bib9","first-page":"v851","article-title":"LBA38_PR: CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (AHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.11.026_bib11","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","article-title":"Nivolumab (NIVO)\u00a0+ ipilimumab (IPI) combination therapy in patients (PTS) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib12","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1002\/hsr2.147","article-title":"Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma","volume":"3","author":"Personeni","year":"2020","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.jhep.2020.11.026_bib13","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib14","article-title":"Clinical significance of de novo malignancy after liver transplant: a single-center study","author":"Kim","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2020.11.026_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/TP.0b013e3181837761","article-title":"Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation","volume":"86","author":"Hoffmann","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2020.11.026_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2013.12.018","article-title":"Risk of hepatobiliary cancer after solid organ transplant in the United States","volume":"12","author":"Koshiol","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib17","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review","volume":"21","author":"de'Angelis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.026_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/2050640619840221","article-title":"Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre","volume":"7","author":"Foerster","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2020.11.026_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10637-011-9726-1","article-title":"Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study","volume":"29","author":"Zhang","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2020.11.026_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1432-2277.2006.00279.x","article-title":"A\u00a0prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma","volume":"19","author":"Soderdahl","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/apt.12132","article-title":"Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma","volume":"37","author":"Shiah","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.11.026_bib23","first-page":"4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J\u00a0Transpl"},{"key":"10.1016\/j.jhep.2020.11.026_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2020.11.026_bib25","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1007\/s00268-012-1533-0","article-title":"Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation","volume":"36","author":"Hwang","year":"2012","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2020.11.026_bib26","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","article-title":"Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series","volume":"22","author":"Sapisochin","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.dld.2011.12.009","article-title":"Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation","volume":"44","author":"Weinmann","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2020.11.026_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.dld.2015.01.001","article-title":"Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis","volume":"47","author":"Mancuso","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2020.11.026_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.transproceed.2013.10.035","article-title":"Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation","volume":"46","author":"De Simone","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2020.11.026_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2020.11.026_bib31","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2020.11.026_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib33","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver allograft failure after nivolumab treatment-a case report with systematic literature research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhep.2020.11.026_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/hiv.12204","article-title":"Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey","volume":"16","author":"Rosenthal","year":"2015","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib36","first-page":"101","article-title":"HIV and the liver","volume":"27","author":"Sherman","year":"2019","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.11.026_bib38","first-page":"3849","article-title":"Non-AIDS defining cancers: a comprehensive update on diagnosis and management","volume":"24","author":"Ceccarelli","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jhep.2020.11.026_bib39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.18.00885","article-title":"Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort study","volume":"37","author":"Pinato","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1634\/theoncologist.2010-0400","article-title":"Hepatocellular carcinoma in HIV-infected patients: check early, treat hard","volume":"16","author":"Berretta","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2020.11.026_bib41","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2020.11.026_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QAD.0000000000001422","article-title":"Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection","volume":"31","author":"Pinato","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2020.11.026_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0000000000001293","article-title":"Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients","volume":"31","author":"Merchante","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2020.11.026_bib44","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CAD.0b013e32835c032f","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients","volume":"24","author":"Berretta","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jhep.2020.11.026_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lci2.15","article-title":"Regorafenib therapy for hepatocellular carcinoma in a HIV-1-infected patient: a case report","volume":"1","author":"Lythgoe","year":"2020","journal-title":"Liver Cancer Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib47","first-page":"379","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jhep.2020.11.026_bib48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of Durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/COH.0000000000000335","article-title":"Hepatocellular carcinoma in patients with HIV","volume":"12","author":"Dika","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jhep.2020.11.026_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919861914","article-title":"The risk of liver cancer in autoimmune liver diseases","volume":"11","author":"Lleo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2017.02.006","article-title":"Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"Tansel","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib52","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/hep.25788","article-title":"Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis","volume":"56","author":"Liang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12072-018-9921-7","article-title":"Liver damage related to immune checkpoint inhibitors","volume":"13","author":"Nishida","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib54","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib55","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17093108","article-title":"Patterns of comorbidity in hepatocellular carcinoma: a network perspective","volume":"17","author":"Mu","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhep.2020.11.026_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/HJH.0000000000002277","article-title":"Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities","volume":"38","author":"Liu","year":"2020","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jhep.2020.11.026_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2020.11.026_bib61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2019.37.4_suppl.317","article-title":"Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)","volume":"37","author":"Sung","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.11.026_bib62","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2019.37.15_suppl.4088","article-title":"Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the phase 3 CELESTIAL trial","volume":"37","author":"Abou-Alfa","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib63","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/annonc\/mdt204","article-title":"Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort","volume":"24","author":"Schlesinger","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2017.04.41","article-title":"Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease","volume":"5","author":"Mantovani","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review","volume":"19","author":"Cunha","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.aohep.2019.11.008","article-title":"Meta-analysis: the efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes","volume":"19","author":"Zhou","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib67","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.2015.1102887","article-title":"Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib","volume":"16","author":"Casadei Gardini","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jhep.2020.11.026_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JHC.S215235","article-title":"Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma","volume":"6","author":"Zakka","year":"2019","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jhep.2020.11.026_bib69","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3748\/wjg.v25.i14.1653","article-title":"Update on hepatocellular carcinoma: pathologists' review","volume":"25","author":"El Jabbour","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.026_bib70","article-title":"Fibrolamellar hepatocellular carcinoma: a population-based observational study","author":"Ramai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.11.026_bib71","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gutjnl-2013-305164","article-title":"Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10","volume":"62","author":"Eggert","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.11.026_bib72","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5858\/arpa.2017-0083-RS","article-title":"Fibrolamellar carcinoma: a concise review","volume":"142","author":"Lin","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1573405614666180927113622","article-title":"State-of-the-art MR imaging of uncommon hepatocellular tumours: fibrolamellar hepatocellular carcinoma and combined Hepatocellularcholangiocarcinoma","volume":"15","author":"Anysz-Grodzicka","year":"2019","journal-title":"Curr Med Imaging Rev"},{"key":"10.1016\/j.jhep.2020.11.026_bib74","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1249484","article-title":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma","volume":"343","author":"Honeyman","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2020.11.026_bib75","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s11605-016-3216-x","article-title":"Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma","volume":"20","author":"Yamashita","year":"2016","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jhep.2020.11.026_bib76","first-page":"3","article-title":"Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium","volume":"6","author":"Ang","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4240\/wjgs.v9.i2.61","article-title":"Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period)","volume":"9","author":"Wahab","year":"2017","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2020.11.026_bib78","doi-asserted-by":"crossref","first-page":"554","DOI":"10.21037\/jgo.2019.01.35","article-title":"Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma","volume":"10","author":"Chakrabarti","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000497464","article-title":"Progression after immunotherapy for fibrolamellar carcinoma","volume":"35","author":"Bauer","year":"2019","journal-title":"Visc Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib80","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.jhep.2020.11.026_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2020.11.026_bib82","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2020.11.026_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib84","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.11.026_bib85","doi-asserted-by":"crossref","first-page":"e15611","DOI":"10.1200\/JCO.2019.37.15_suppl.e15611","article-title":"Lenvatinib for the treatment of HCC: a single institute experience","volume":"37","author":"San-Chi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib86","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2016.4115","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score","volume":"3","author":"Zhu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib88","doi-asserted-by":"crossref","unstructured":"El-Khoueiry A, Meyer T, Cheng A, Rimassa L, Sen S, Milwee S, et\u00a0al. Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs. placebo. abstract ESMO 2020;SO-9.","DOI":"10.1016\/j.annonc.2020.04.024"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2020.11.026_bib89","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2019.37.4_suppl.327","article-title":"Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status","volume":"37","author":"Kudo","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib90","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A\u00a0global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib92","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib93","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib94","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1872-034X.2011.00778.x","article-title":"Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib","volume":"41","author":"Morimoto","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00280-014-2645-z","article-title":"Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors","volume":"75","author":"Edeline","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2020.11.026_bib96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hepr.13427","article-title":"Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching","volume":"50","author":"Tada","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib97","doi-asserted-by":"crossref","unstructured":"Li D, Toh H, Merle P, Tsuchiya K, Hernandez S, Shao H, et\u00a0al. Atezolizumab\u00a0+ bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (HCC): results from older adults enrolled in IMbrave150. ESMO World Congress on Gastrointestinal Cancer 2020;Virtual. Abstract 0-8.","DOI":"10.1016\/j.annonc.2020.04.061"},{"issue":"15_suppl","key":"10.1016\/j.jhep.2020.11.026_bib98","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1200\/JCO.2018.36.15_suppl.4090","article-title":"Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"36","author":"Rimassa","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2020.11.026_bib99","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/liv.14462","article-title":"Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2","volume":"40","author":"Kudo","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib100","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib101","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-09-2684","article-title":"Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse","volume":"16","author":"Jain","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib102","doi-asserted-by":"crossref","first-page":"e201250","DOI":"10.1001\/jamaoncol.2020.1250","article-title":"Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: a multicenter phase 2 trial","volume":"6","author":"Miyamoto","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib103","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/hepr.12354","article-title":"Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis","volume":"45","author":"Morimoto","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib104","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study","volume":"35","author":"Reiss","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJM199904013401302","article-title":"Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding","volume":"340","author":"Sarin","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.11.026_bib106","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cgh.2013.02.026","article-title":"Coagulation in liver disease: a guide for the clinician","volume":"11","author":"Northup","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib107","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.2012.48.4857","article-title":"Contraindicated use of bevacizumab and toxicity in elderly patients with cancer","volume":"31","author":"Hershman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102961","article-title":"Vascular complications in patients with hepatocellular carcinoma treated with sorafenib","volume":"12","author":"Pomej","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2020.11.026_bib109","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A\u00a0phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.11.026_bib110","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA approval summary: ramucirumab for gastric cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib111","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.26120","article-title":"Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies","volume":"57","author":"Duffy","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib112","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib113","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib114","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-16-3171","article-title":"Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma","volume":"23","author":"Duffy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hep.20339","article-title":"Improved survival after variceal bleeding in patients with cirrhosis over the past two decades","volume":"40","author":"Carbonell","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib116","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib118","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jjco\/hys100","article-title":"High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or \u2018uremia\u2019? a population-based study","volume":"42","author":"Hwang","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib119","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1744-9987.12563","article-title":"Characteristics and prognosis of hepatocellular carcinoma in Japanese patients undergoing dialysis","volume":"21","author":"Toyoda","year":"2017","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jhep.2020.11.026_bib120","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib121","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/liv.14436","article-title":"International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis","volume":"40","author":"Diaz-Gonzalez","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib122","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminoncol.2020.05.001","article-title":"Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systemic review","volume":"47","author":"Klajer","year":"2020","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib123","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/tri.13353","article-title":"Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis","volume":"31","author":"Zanetto","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib124","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.thromres.2007.10.009","article-title":"Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma","volume":"122","author":"Connolly","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib125","first-page":"169","article-title":"New evidence and perspectives on the management of hepatocellular carcinoma with portal vein tumor thrombus","volume":"5","author":"Yin","year":"2017","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib126","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.13988","article-title":"Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse?","volume":"39","author":"Mahringer-Kunz","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.11.026_bib127","first-page":"499","article-title":"Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein","volume":"54","author":"Shuqun","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2020.11.026_bib128","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib129","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.11.026_bib131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2020.11.026_bib132","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.21873\/anticanres.14193","article-title":"Sorafenib vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"40","author":"Kuzuya","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhep.2020.11.026_bib133","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.29225","article-title":"Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey","volume":"66","author":"Kokudo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.11.026_bib134","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2020.11.026_bib135","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.11.026_bib136","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","article-title":"Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"82","author":"Choi","year":"2018","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:08Z","timestamp":1759174868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820338137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0168827820338137"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatment of HCC in special populations","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}